Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy

Candace B Mainor; Alison P Duffy; Kristin L Atkins; Amy S Kimball; Maria R Baer

doi:10.1177/1078155214568582

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy

J Oncol Pharm Pract. 2016 Apr;22(2):374-7. doi: 10.1177/1078155214568582. Epub 2015 Jan 23.

Authors

Candace B Mainor¹, Alison P Duffy², Kristin L Atkins³, Amy S Kimball⁴, Maria R Baer⁴

Affiliations

¹ Department of Medicine, University of Maryland School of Medicine, Baltimore, USA cmainor@umm.edu.
² Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, USA.
³ Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, USA.
⁴ Department of Medicine, University of Maryland School of Medicine, Baltimore, USA Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, USA.

PMID: 25616656
DOI: 10.1177/1078155214568582

Abstract

BCR-ABL inhibitors administered in conjunction with chemotherapy have significantly improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia but, for patients diagnosed during pregnancy, data on risks to the fetus are limited. We report a woman treated with chemotherapy and imatinib mesylate who delivered a healthy baby at 30 weeks, and we discuss available data.

Keywords: Acute lymphoblastic leukemia; imatinib mesylate; pregnancy.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Female
Humans
Imatinib Mesylate / therapeutic use*
Infant, Newborn
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Pregnancy
Pregnancy Complications, Neoplastic / diagnosis
Pregnancy Complications, Neoplastic / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents
Imatinib Mesylate